The post As per a peer-reviewed Lancet study, the efficacy of covaxin is 77.8% appeared first on The Edge Media.
]]>
According to the Lancet study, the vaccination produces a strong antibody response. There were no serious vaccine-related adverse events or deaths among the trial participants. The bulk of the side effects, such as headaches, weariness, fever, and injection site soreness, were minor and occurred within seven days following immunization.
The post As per a peer-reviewed Lancet study, the efficacy of covaxin is 77.8% appeared first on The Edge Media.
]]>The post Covid-19: According to Mandaviya, India has two of the eight WHO-approved vaccinations appeared first on The Edge Media.
]]>
On November 3, the World Health Organization’s technical advisory team endorsed Bharat Biotech’s Covaxin for EUL for people aged 18 and up. “Reflecting worldwide acceptance of India’s vaccines and our vaccination process, 96 countries have agreed to Mutual Acceptance of Vaccination Certificates,” the minister was quoted as saying by news agency ANI, adding the list can be checked via CoWIN app.
The post Covid-19: According to Mandaviya, India has two of the eight WHO-approved vaccinations appeared first on The Edge Media.
]]>The post The government is looking into a new Delta subvariant, and the WHO has approved Covaxin: Here’s What Health Minister Said appeared first on The Edge Media.
]]>
At a press conference, the Union Health Minister said: “A team is investigating the new Covid-19 variant AY.4.2 … ICMR and NCDC teams will study and analyze the different variants.”
On the emergency approval of Bharat Biotech’s Covaxin, the health minister stated that WHO will make the decision based on today’s meeting.
The post The government is looking into a new Delta subvariant, and the WHO has approved Covaxin: Here’s What Health Minister Said appeared first on The Edge Media.
]]>The post According to a WHO official, Bharat Biotech’s Covid vaccine could be approved “within the next 24 hours” appeared first on The Edge Media.
]]>
“If all is in place and all goes well and if the committee is satisfied, we would expect a recommendation within the next 24 hours or so,” Margaret Harris told journalists at a UN press briefing.
On April 19, Bharat Biotech, based in Hyderabad, submitted an EOI (Expression of Interest) to the WHO for the vaccine’s Emergency Use Listing (EUL).
The post According to a WHO official, Bharat Biotech’s Covid vaccine could be approved “within the next 24 hours” appeared first on The Edge Media.
]]>The post In authorizing India’s Covaxin injection, the WHO said it “cannot take corners” appeared first on The Edge Media.
]]>
Bharat Biotech, which collaborated with an Indian governmental research entity to produce Covaxin, began sharing data with the WHO in early July. Even before the end of a late-stage trial, which found the vaccination to be 78 percent effective, the vaccine was given emergency use authorization in India in January.
The post In authorizing India’s Covaxin injection, the WHO said it “cannot take corners” appeared first on The Edge Media.
]]>The post Centre issues guidelines to help people identify authentic vaccines appeared first on The Edge Media.
]]>According to the Union ministry of health and family welfare, 684.6 million vaccine doses against Covid-19 have been administered so far in the country. “With the administration of 71,61,760 vaccine doses in the last 24 hours, India’s COVID-19 vaccination coverage has surpassed the cumulative figure of 68.46 Crore (68,46,69,521) on Sunday,” the health ministry said.
Here are the various parameters to identify if a Covid-19 vaccine is original:
How to check whether the Covishield vaccine is original?
* The SII product’s label shade is dark green and the colour of the aluminium flip-off seal is dark green.
*The brand name with the trademark is mentioned on the original vaccine.
*The lettering is printed in special white ink to be more clear and readable.
* The text font of the Generic name is in un-bold
* Overprinted with “CGS NOT FOR SALE”.
* The SII logo is printed at a unique angle and position which can be identified by only a select few who are aware of the exact details.
* The lettering is printed in special white ink to be more clear and readable.
* The entire label has been given a special honeycomb effect, which is visible only at a specific angle.
*The honeycomb design has been altered slightly at strategic locations and certain additional special elements added to the texture design. They are not visible to people in general but those who know about the subtle changes can easily check and verify the authenticity of the label and vial.
How to check Covaxin’s authenticity?
* There is an invisible UV helix or a DNA-like structure on the Covaxin label. It is only visible under UV light
* The micro text hidden in the label claims Dots, which is written as Covaxin
* There is a green foil effect in X of Covaxin.
* There is a holographic effect on Covaxin
How to find out if Sputnik V vaccine is not fake?
* There are different labels for the two bulk manufacturing sites where the Russian Covid-19 vaccine is produced. All other information and design are the same except the manufacturer’s name.
* The English label is available only on the front and back of the carton of 5 ampoule pack for all the imported products so far. All other sides, including the primary label on the vaccine ampoule, is in Russian script.
(With agency inputs)
The post Centre issues guidelines to help people identify authentic vaccines appeared first on The Edge Media.
]]>The post A mix of Covishield and Covaxin can actually yield better results : ICMR appeared first on The Edge Media.
]]>The study was only conducted on 18 people of Uttar Pradesh’s Siddharth Nagar, who by mistake received two doses of two separate vaccines. According to the finding of the study which is yet to be peer-reviewed immunisation with a combination of an adenovirus vector platform-based vaccine, followed by inactivated whole virus vaccine was not only safe but also elicited better immunogenicity.
Covishield, manufactured by Pune’s Serum Institute of India, is the adenovirus vector platform-based vaccine and Covaxin, developed and manufactured by Bharat Biotech and the ICMR, is the whole virus vaccine. Covishield and Covaxin belong to two different types.
The study titled ‘Serendipitous Covid-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous Regime’ has been uploaded on medRxiv. Under this study, 18 people received two doses of two different vaccines, the reaction of which was compared to 40 receipients of two doses of Covishield and 40 recipients of two doses of Covaxin, news agency PTI reported. The study duration was from May to June 2021, it said.
Mixing of vaccines is being discussed globally all studies are in favour of mixing two vaccines to increase the protection against future infection. The subject expert committee of the Central Drugs Standard Control Organisation has in July recommended a trial of mixing Covishield and Covaxin, which will be conducted by the Christian Medical College in Vellore on 300 healthy volunteers.
While that will be a proper clinical trial to investigate the effectiveness of the cocktail of Covishield and Covaxin, the ICMR’s study was based on the goof-up that took place in May. There was no immediate adverse impact of the mix-up of the beneficiaries. Now, further study has revealed that the mix-up has actually worked in favour of protection as these people have more protection than those who have received two shots of the same vaccine.
The issue of mixing vaccines is sensitive as World Health Organization has warned that individuals should not decide on mixing vaccines. Niti Aayog member (health) Dr VK Paul had earlier said that theoretically there is no problem in mixing two vaccines as the second dose in such a case will work as a booster shot. But as the government started its vaccination drive on January 16, it asked health workers to exercise extreme caution to make sure that the beneficiaries receive the second shot of the same vaccine that they received as their first shots.
The post A mix of Covishield and Covaxin can actually yield better results : ICMR appeared first on The Edge Media.
]]>The post Monthly production capacity of vaccines to be increased : Centre appeared first on The Edge Media.
]]>Union Health Minister Mansukh Mandaviya was responding to a question on the current capacity to manufacture Covaxin and Covishield in the country, and the expected capacity going forward from August to December 2021.
“As communicated by the manufacturers, the monthly vaccine production capacity of Covishield is projected to be increased from 110 million doses per month to more than 120 million doses per month and the production capacity of Covaxin is projected to be increased from 25 million doses per month to around 58 million doses per month,” the minister said in a written reply.
Further, the Department of Biotechnology under the Ministry of Science and Technology has launched ‘Mission Covid Suraksha – the Indian COVID-19 Vaccine Development Mission’.
The Mission is being implemented by Biotechnology Industry Research Assistance Council (BIRAC), a public sector undertaking (PSU) of the Department of Biotechnology, the reply stated.
Under the Mission, facility augmentation of Bharat Biotech and one state public sector enterprise and 2 central public sector enterprises (PSEs) – Haffkine Biopharmaceutical Corporation Ltd, Mumbai; Indian Immunologicals Limited (IIL), Hyderabad and Bharat Immunologicals Biologicals Limited (BIBCOL), Bulandshahr – for production of Covaxin have been supported.
In addition, technology transfer of Covaxin production to Gujarat COVID Vaccine Consortium (GCVC), including Hester Biosciences and OmniBRx Biotechnologies Pvt Ltd, led by Gujarat Biotechnology Research Centre (GBRC) of Department of Science and Technology, Government of Gujarat, has also been facilitated, the reply said.
Further, the Centre has also extended financial assistance to one of the domestic manufacturers for ‘At-risk manufacturing’, advance payment against the supply orders placed with Serum Institute of India and Bharat Biotech, besides streamlining regulatory norms for approval of vaccines, the reply added.
(Except for the headline, this story has not been edited by The Edge Media staff and is published from a syndicated feed.)
The post Monthly production capacity of vaccines to be increased : Centre appeared first on The Edge Media.
]]>The post Bharat Biotech Put A Stop To Brazilian Agreement Of Vaccine Supply appeared first on The Edge Media.
]]>Precisa Medicamentos is Bharat Biotech’s Brazilian partner, assisting, guiding, and supporting the company with regulatory filings, licensing, sales, coverage, and the performance of phase III clinical studies, among other things.
According to the company, Bharat Biotech is pursuing licences in numerous nations based on the legal criteria of each country.
The post Bharat Biotech Put A Stop To Brazilian Agreement Of Vaccine Supply appeared first on The Edge Media.
]]>The post Bharat Biotech To Supply 500M Covaxin Doses To Center appeared first on The Edge Media.
]]>Bharati Pravin Pawar, Minister of State for Health, stated in Parliament on Tuesday that the Serum Institute of India furnished the Centre with 5.45 crore (54.5 million) doses of Covaxin by Bharat Biotech and 36.01 crores (360 million) doses of Covishield from January to July 16.
The post Bharat Biotech To Supply 500M Covaxin Doses To Center appeared first on The Edge Media.
]]>